Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018861 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT02018861 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 88 participants.
The verdict
NCT02018861, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.
Interventions
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Ifosfamide
- DRUG Itacitinib
- DRUG Parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2016-09-22 |
| Est. Completion | 2021-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018861
The ClinicalTrials.gov registry entry for NCT02018861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02018861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018861 about?
NCT02018861 is a clinical study titled "A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)". Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ...
What is the current status of trial NCT02018861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2016-09-22. Estimated completion is 2021-04-12.
What interventions are being tested in trial NCT02018861?
The interventions under investigation include: Carboplatin (DRUG), Rituximab (DRUG), Ifosfamide (DRUG), Itacitinib (DRUG), Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT02018861?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.